Clinical Trial Search

Primary: Zicam Was Compared to Placebo as a Treatment of Recurrent HSL From the Date and Time of the Initiation of Therapy Until the Date and Time of Resolution of the Lesion or…

Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716

Primary: Lesion Healing — 107.47; 110.08; 112.41 hours

Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)

Primary: Subjects With at Least One Form of Contact With Study Staff With no Herpes Labialis Outbreaks Within 119 Days of Sensitization — 62.96; 20 percentage of particpants

Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05

Primary: Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's Assessment — 21.8; 16.4; 19.9; 78.2 percentage of partcipants…

Primary: Days to Next Herpes Labialis (Cold Sore) Episode From 43 Days After the First Dose up to 121 Days After the First Dose — 128; 163; 174 days

Primary: Percentage of Participants With Healing by Day 8 — 194 Participants

Primary: Time to Healing (TTH) of Vesicular Primary Lesion — 7.00; 7.32 Days — p=0.015

Primary: Duration (Days) of Herpes Labialis Outbreak Until Healed — 10.6; 8.25 days

Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…

Primary: Number of Participants Reported Adverse Events (AEs), Serious Adverse Events (SAEs) — 6; 6; 0; 0 Participants

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment.(Motor Scores) — 0; 3; 0; 0 Participants

Primary: Clinical Assessment Performed by the Investigator and Skin Temperature at the Cold Sore. — 39; 32 participants

Primary: Mean Change From Baseline in Blood Flow — 2558.65; 3470.13; 809.88; 960.86 Perfusion Units — p=0.3061

Primary: Reporting of Adverse Events — 9 participants

Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001

Primary: Serious Adverse Device Effects — 0 Percentage SADE's

Primary: Number of Participants for Whom a Recurrent Oral Herpes Episode Initiated With Prodromal Symptoms Were Aborted Before Progressing to a Lesion as Assessed by a Trained…

Primary: Percentage of Participants With Healing by Day 8 — 66.4; 69.5 Percentage of Participants — p=0.5086

Primary: Number of Participants With Bacterial Vaginosis Recurrence — 8 Participants

Primary: Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation — -0.53; 0.03 log10 copies/mL

Primary: Survival With no or Mild Neuropsychological Impairment at 12 Months After Initiation of Study Medication as Measured by the Mattis Dementia Rating Scale (MDRS) — 28; 34…

Primary: HSV Shedding Rate in Those Receiving Oral TDF, Vaginal TFV, or Double Placebo — 22.9; 13.8; 21.3; 19.5 percentage of swabs positive (%) — p=0.086

Primary: Investigator Assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 5.38; 4.79 Days — p=0.4161

Primary: The Quantity of HIV-1 RNA in Plasma While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir. — 4.08; 3.68 log10 copies/mL — p=<0.001

Primary: Clinician Assessed Duration of the Classical Herpetic Lesion — 162.7; 163.6 hours

Primary: Time to Healing of Genital Lesions — 5.1; 6.0 Days

Primary: Herpes Simplex Virus Type 2 Recurrence — 0; 0 Recurrence